Earnings digests and industry comparisons for Japan's biggest listed companies.
640 reports(page 26 of 54)
Otsuka reported that its subunit Daio has achieved a significant progression-free survival extension in treating advanced non-small cell lung cancer. The phase 3 trial showed hazard ratios of 0.50, highlighting the potential for a new treatment standard.
Hanwa will cancel 10.33 million treasury shares, reducing its total issued shares by 4.9 percent. This capital policy aims to boost earnings per share and enhance shareholder value through significant equity reduction.
Chubu Electric will withdraw its license application for the Hamadora nuclear units, citing critical doubts regarding data reliability. This decision halts the re-examination process pending trust restoration.
Chubu Electric disclosed a report confirming it provided false explanations regarding seismic motion calculations for the Hamamoto nuclear plant. This revelation of fraudulent conduct during regulatory reviews significantly delays the path to reactor restart.
Takeda reported that the US Food and Drug Administration has accepted its new drug application for the psoriasis treatment zasocitinib. The approval target date is set for the first quarter of 2027 following the priority review status.
Leopalace21 has resolved to cut dividends to zero for the fiscal year ending March 2027, aligning with support from tender offeror K891. This decision paves the way for a delisting and effectively pauses shareholder returns during the transition.
Leopalace21 has approved a tender offer from a consortium led by Kocom at JPY1,000 per share. The bid represents a 52 percent premium and clarifies the path toward delisting.
Chubu Electric has received an investigation report confirming flaws in the seismic motion evaluation method for the Hamama nuclear power plant. The disclosure highlights significant internal control defects, leaving the path to restart unclear and business impacts undetermined.
Sanwa announced the completion of its treasury stock acquisition program on October 1, having purchased an additional 320,000 shares in September. The consumer retail group effectively utilized its entire 10 billion yen budget, marking a robust commitment to shareholder returns.
Tokyo Century has decided to issue ¥20 billion in subordinated hybrid bonds to reinforce its financial foundation. The annual interest rate will be capped at 3.245 percent, aiming to strengthen the core surplus capital ratio.
Kakaku.com bidder Kamgras1 raised its TOB price to 3,680 yen per share. The move aims to rival Bain Capital's proposal and may lead to a merger or renewed competition for the privatization deal.
Machine tool giant Tsugami announced the early termination of its share buyback program as of September 10, 2026. The company purchased shares representing 92.00 percent of the approved limit.
